Loading...
XKRX007570
Market cap163mUSD
Jan 06, Last price  
13,290.00KRW
1D
8.76%
1Q
3.10%
Jan 2017
-68.09%
Name

Ilyang Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XKRX:007570 chart
P/E
20.74
P/S
0.92
EPS
640.94
Div Yield, %
1.62%
Shrs. gr., 5y
-0.26%
Rev. gr., 5y
-2.90%
Revenues
259.04b
-32.51%
129,862,634,000120,289,302,000114,614,743,000147,689,522,000138,485,382,000141,162,847,320146,460,716,530147,731,713,180211,797,503,490186,285,485,380261,614,907,970269,811,002,650300,036,331,830324,573,436,600343,328,723,950371,347,508,040383,810,821,780259,042,263,250
Net income
11.52b
-63.71%
3,110,883,0001,003,252,000-16,079,811,0001,065,748,0001,975,802,0001,386,265,0502,073,286,5903,963,178,000-10,961,991,0003,617,616,0005,905,742,0006,264,568,000-4,893,034,00019,594,666,72021,545,309,78025,955,713,96031,741,017,76011,519,585,560
CFO
19.38b
-35.25%
5,645,343,000-2,875,366,000-1,631,673,000-9,441,306,00015,474,104,000-26,621,705,9304,426,532,760-3,036,392,13018,628,602,71021,788,068,54027,040,532,73030,025,336,00022,120,200,80036,192,694,56057,484,189,26067,020,184,27029,936,129,02019,382,377,881
Dividend
Dec 27, 2023150 KRW/sh
Earnings
Jan 31, 2025

Profile

Ilyang Pharmaceutical Co.,Ltd operates as a pharmaceutical company primarily in South Korea. The company offers anticancer, circulatory system, endocrine/metabolism, cheonjiyang, female hormone, urinary system, ophthalmology, liver disease, anti-inflammatory analgesic, digestive system, dermatology, respiratory system, nutrient infusion, and neurology medicines. It also provides antibiotics, antifungal drugs, anti-inflammatory analgesic drugs, insecticides, and vaccines; and health drinks, daily food, supplements, health food, cosmetics, and beverages. In addition, the company offers pharmaceutical raw materials products, such as aluminum hydroxide gel, dried aluminum hydroxide gel, magnesium hydroxide, magnesium hydroxide gel, aluminum hydroxide-magnesium carbonate co-dried gel, magnesium trisilicate, hydrotalcite, almagate, aluminum phosphate, aluminum phosphate gel, aluminum magnesium metasilicate, aluminum magnesium silicate, aluminum magnesium silicopolydrate, magaldrate, magaldrate wet gel, dihydroxy aluminum sodium carbonate, magnesium carbonate, aluminum magnesium hydroxide, synthetic aluminum silicate, and other products. Ilyang Pharmaceutical Co.,Ltd also exports its products to approximately 14 countries. The company was formerly known as Il-Yang Pharm. Ind. Co. and changed its name to Ilyang Pharmaceutical Co., Ltd. in May 1991. Ilyang Pharmaceutical Co.,Ltd was founded in 1946 and is headquartered in Yongin, South Korea.
URL
http://www.ilyang.co.kr/
IPO date
Aug 28, 1974
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122015‑03
Income
Revenues
259,042,263
-32.51%
383,810,822
3.36%
Cost of revenue
196,637,975
290,304,553
Unusual Expense (Income)
NOPBT
62,404,288
93,506,268
NOPBT Margin
24.09%
24.36%
Operating Taxes
1,432,324
9,590,386
Tax Rate
2.30%
10.26%
NOPAT
60,971,964
83,915,882
Net income
11,519,586
-63.71%
31,741,018
22.29%
Dividends
(3,875,710)
(3,942,260)
Dividend yield
1.37%
1.12%
Proceeds from repurchase of equity
(1,999,978)
(3,000,037)
BB yield
0.71%
0.86%
Debt
Debt current
66,047,731
84,982,677
Long-term debt
6,832,165
1,835,900
Deferred revenue
17,042
Other long-term liabilities
7,424,886
8,409,010
Net debt
29,505,180
24,266,579
Cash flow
Cash from operating activities
19,382,378
29,936,129
CAPEX
(12,004,895)
(20,535,293)
Cash from investing activities
(62,608,154)
7,585,457
Cash from financing activities
(6,481,974)
(23,395,566)
FCF
57,173,510
68,762,461
Balance
Cash
18,908,255
65,015,982
Long term investments
24,466,460
(2,463,983)
Excess cash
30,422,603
43,361,458
Stockholders' equity
141,000,141
224,352,543
Invested Capital
200,122,137
337,643,115
ROIC
22.68%
24.73%
ROCE
25.08%
23.89%
EV
Common stock shares outstanding
18,019
18,125
Price
15,650.00
-19.12%
19,350.00
-31.02%
Market cap
281,994,502
-19.60%
350,728,019
-31.32%
EV
348,683,294
433,307,756
EBITDA
70,783,233
106,570,983
EV/EBITDA
4.93
4.07
Interest
3,215,846
2,458,795
Interest/NOPBT
5.15%
2.63%